The mechanism researches revealed that rapamycin (an autophagy activator) pre-treatment could mitigate inflammatory injury of liver by inhibiting NLRP3 inflammasome activation and reducing the levels of NLRP3, IL-1β and IL-18 in KCs with hepatic I/R injury, whereas 3-MA (an autophagy inhibitor) pre-treatment reversed the effects. The gene discussed is IL18; the disease is dry eye syndrome.